When to Perform Preoperative Bone Scintigraphy for Kidney Cancer Staging : Indications for Preoperative Bone Scintigraphy - 22/11/17
, Fabio Muttin a, Nicola Fossati a, b, Paolo Dell'Oglio a, Ettore Di Trapani a, Armando Stabile a, Francesco Ripa a, Francesco Trevisani a, Cristina Carenzi a, Maria Picchio c, Alberto Briganti a, Andrea Salonia a, Alexandre Mottrie b, Roberto Bertini a, Francesco Montorsi a, Umberto Capitanio aAbstract |
Objective |
To identify an objective and reproducible strategy for preoperative staging bone scintigraphy (BS) in patients diagnosed with renal cell carcinoma (RCC), because in the absence of objective criteria, the decision to perform preoperative BS remains a subjective practice.
Patients and Methods |
The study included a total of 2008 patients with RCC treated with surgery and prospectively included into an institutional database. The study outcome was the presence of 1 or more bone lesions suspicious for metastases at staging BS. A multivariable logistic regression model predicting a positive BS was fitted. The predictors consisted of the preoperative clinical tumor (cT) and clinical nodal (cN) stages, the presence of systemic symptoms, and the platelet-to-hemoglobin (PLT/Hb) ratio.
Results |
The rate of positive BS was 4% (n = 81). At the multivariable logistic regression analysis, cT2, cN1, the presence of systemic symptoms, and the PLT/Hb ratio were all associated with am increased risk of positive BS (P <.05). Following the 2000-sample bootstrap validation, the concordance index was 0.77 (proposed model) vs 0.63 (decision making based on symptoms only). At the decision curve analysis, the proposed strategy was associated with a higher net benefit. If BS is performed when the risk of positive result is >5%, a negative BS is spared in 80% and a positive BS is missed in 2% of the population only.
Conclusion |
Using preoperative variables, it is possible to accurately estimate the risk of positive BS at RCC staging using preoperative characteristics. Compared with the strategy supported by available guidelines, the proposed model was more objective, statistically more accurate, and clinically associated with higher net benefit.
Le texte complet de cet article est disponible en PDF.Plan
| Financial Disclosure: The authors declare that they have no relevant financial interests. |
Vol 110
P. 114-120 - décembre 2017 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
